Literature DB >> 35639173

Association between non-alcoholic fatty liver disease and bone turnover markers in southwest China.

Ying Liu1,2, Ping Shuai1,2, Yuping Liu1,2, Dongyu Li3,4.   

Abstract

INTRODUCTION: Non-alcoholic fatty liver disease (NAFLD) is not considered only a liver disease but also associated with an increased risk of extra-hepatic diseases including bone metabolism disorders. In our study, we aim to explore the changes of several bone turnover markers (BTMs) under different fat deposition and stiffness levels of the liver.
MATERIALS AND METHODS: We analyzed the physical examination data of 3353 subjects from February 2018 to June 2021 in this study. The steatosis and stiffness of liver were quantitatively detected using the fat attenuation parameter (FAP) and liver stiffness measurements (LSM) of transient elastography (TE). Serum 25-hydroxyvitamin D3 (25(OH)D3), osteocalcin, carboxy-terminal collagen crosslinks (CTX), amino terminal elongation peptide of total type 1 procollagen (P1NP) were tested. Clinical and other biochemical data were also collected.
RESULTS: With the increasing of FAP, the levels of 25(OH)D3 and osteocalcin decreased, the difference was statistically significant. No correlation was found between LSM and all the four BTMs. Logistic regression analysis revealed that FAP ≥ 244 dB/m was negatively correlated with 25(OH)D3 (in both males and females) and osteocalcin (only in males). No correlation was found between FAP ≥ 244 dB/m and P1NP or CTX.
CONCLUSION: The degree of liver adipose deposition was found to be negatively associated with the serum levels of 25(OH)D3 (in both males and females) and osteocalcin (only in males) in southwest China.
© 2022. The Japanese Society Bone and Mineral Research.

Entities:  

Keywords:  Bone turnover marker; Fat attenuation parameter; Liver stiffness measurement; Metabolic syndrome; Non-alcoholic fatty liver disease

Mesh:

Substances:

Year:  2022        PMID: 35639173     DOI: 10.1007/s00774-022-01340-8

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  29 in total

1.  Controlled attenuation parameter (CAP): a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes.

Authors:  Magali Sasso; Michel Beaugrand; Victor de Ledinghen; Catherine Douvin; Patrick Marcellin; Raoul Poupon; Laurent Sandrin; Véronique Miette
Journal:  Ultrasound Med Biol       Date:  2010-09-27       Impact factor: 2.998

Review 2.  Nonalcoholic fatty liver disease and decreased bone mineral density: is there a link?

Authors:  G Targher; A Lonardo; M Rossini
Journal:  J Endocrinol Invest       Date:  2015-05-24       Impact factor: 4.256

Review 3.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 4.  Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases.

Authors:  Leon A Adams; Quentin M Anstee; Herbert Tilg; Giovanni Targher
Journal:  Gut       Date:  2017-03-17       Impact factor: 23.059

Review 5.  Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention.

Authors:  Zobair Younossi; Quentin M Anstee; Milena Marietti; Timothy Hardy; Linda Henry; Mohammed Eslam; Jacob George; Elisabetta Bugianesi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-09-20       Impact factor: 46.802

6.  [Comparison of FibroTouch and FibroScan for the assessment of fibrosis in chronic hepatitis B patients].

Authors:  Xiaojuan Ou; Xiaoming Wang; Xiaoning Wu; Yuanyuan Kong; Weijia Duan; Jialing Zhou; Dongyang Sun; Yu Wang; Hong You; Jidong Jia
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2015-02

Review 7.  Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.

Authors:  György Baffy; Elizabeth M Brunt; Stephen H Caldwell
Journal:  J Hepatol       Date:  2012-02-09       Impact factor: 25.083

8.  Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Ying Qu; Yan-Yan Song; Cheng-Wei Chen; Qing-Chun Fu; Jun-Ping Shi; Yun Xu; Qing Xie; Yong-Feng Yang; Yong-Jian Zhou; Liang-Ping Li; Ming-Yi Xu; Xiao-Bo Cai; Qi-Di Zhang; Hao Yu; Jian-Gao Fan; Lun-Gen Lu
Journal:  Clin Transl Gastroenterol       Date:  2021-04-13       Impact factor: 4.396

Review 9.  Liver stiffness: a novel parameter for the diagnosis of liver disease.

Authors:  Sebastian Mueller; Laurent Sandrin
Journal:  Hepat Med       Date:  2010-05-25

10.  Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults.

Authors:  Toshihiro Umehara
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.